Results 81 to 90 of about 44,308 (198)
European Journal of Haematology, EarlyView.ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley +1 more source
Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report
Journal of Medical Case Reports, 2022 Background Mantle cell lymphoma is the rarest subtype of non-Hodgkin’s lymphoma. It can exhibit diverse extranodal manifestations. However, renal involvement is uncommon, and if it occurs, it usually only gets detected postmortem.
Hasan Nassereldine +5 more
doaj +1 more source
European Journal of Haematology, EarlyView.ABSTRACT Primary cutaneous B‐cell lymphomas (CBCL) represent a clinically and biologically heterogeneous group of extranodal non‐Hodgkin lymphomas confined to the skin at the time of diagnosis. They account for approximately 25% of all primary cutaneous lymphomas and are subclassified into distinct entities according to the World Health Organization ...
A. Bernardelli +5 more
wiley +1 more source
Biological functions of CDK5 and potential CDK5 targeted clinical treatments. [PDF]
, 2017 Cyclin dependent kinases are proline-directed serine/threonine protein kinases that are traditionally activated upon association with a regulatory subunit.
Casimiro, Mathew C. +2 more
core +2 more sources
Ubiquitination dynamics in human tumour viruses: Viral infection, oncogenesis and antiviral therapy
The FEBS Journal, EarlyView.The ubiquitin system is essential for cellular homeostasis and regulates many processes. Viruses, including oncogenic ones, exploit or evade this system to survive and replicate. This review explores how human tumour viruses manipulate the ubiquitination system to complete their life cycle, evade immunity and promote cancer.
Oscar Trejo‐Cerro +2 more
wiley +1 more source
Haematologica, 2018 Mantle cell lymphoma patients have variable clinical courses, ranging from indolent cases that do not require immediate treatment to aggressive, rapidly progressing diseases.
Riccardo Bomben +20 more
doaj +1 more source
A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms [PDF]
, 2011 Background: Alterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas. However, most epigenetic studies in hematologic neoplasms (HNs) have focused either on the analysis of few candidate genes or many genes and few HN entities,
Agirre, Xabier +34 more
core
eJHaem, Volume 6, Issue 6, December 2025.ABSTRACT Introduction Chimeric antigen receptor T‐cell (CART) therapy has shown clinical efficacy in relapsed and refractory large B‐cell malignancies. There is emerging data on the long‐term complications including risk of secondary malignancies. We aimed to describe the incidence and characteristics of secondary malignancies following CART therapy ...
Joanne Britto +9 more
wiley +1 more source
American Journal of Hematology, Volume 100, Issue 11, Page 2064-2073, November 2025.Idiopathic Multicentric Castleman Disease. ABSTRACT Idiopathic multicentric Castleman disease (iMCD) is a rare cytokine‐driven disorder characterized by systemic inflammation, organ dysfunction, and altered lymph node microscopic architecture. Over the past decade, diagnostic criteria have evolved significantly, integrating clinical, histopathological,
FNU Alnoor +11 more
wiley +1 more source
Haematologica, 2010 Background The aim of this study was to validate the Mantle Cell Lymphoma International Prognostic Index in a population-based cohort and to study the relevance of its revisions.Design and Methods We analyzed data from 178 unselected patients with stage ...
Saskia A.M. van de Schans +4 more
doaj +1 more source